Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement. It displays high oral bioavailability and water solubiltiy compared to other magnesium salts such as magnesium citrate, magnesium carbonate and magnesium oxide.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium aspartate. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium aspartate. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium aspartate. |
| Cisatracurium | Magnesium aspartate may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium aspartate. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium aspartate. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium aspartate. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium aspartate. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium aspartate. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium aspartate. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium aspartate. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium aspartate. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium aspartate. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium aspartate. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium aspartate. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium aspartate. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium aspartate. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium aspartate. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium aspartate. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Magnesium aspartate. |
| Calcitriol | The serum concentration of Magnesium aspartate can be increased when it is combined with Calcitriol. |
| Calcifediol | The serum concentration of Magnesium aspartate can be increased when it is combined with Calcifediol. |
| Ergocalciferol | The serum concentration of Magnesium aspartate can be increased when it is combined with Ergocalciferol. |
| Cholecalciferol | The serum concentration of Magnesium aspartate can be increased when it is combined with Cholecalciferol. |
| Paricalcitol | The serum concentration of Magnesium aspartate can be increased when it is combined with Paricalcitol. |
| Dihydrotachysterol | The serum concentration of Magnesium aspartate can be increased when it is combined with Dihydrotachysterol. |
| Alfacalcidol | The serum concentration of Magnesium aspartate can be increased when it is combined with Alfacalcidol. |
| Seocalcitol | The serum concentration of Magnesium aspartate can be increased when it is combined with Seocalcitol. |
| Inecalcitol | The serum concentration of Magnesium aspartate can be increased when it is combined with Inecalcitol. |
| Becocalcidiol | The serum concentration of Magnesium aspartate can be increased when it is combined with Becocalcidiol. |
| Eldecalcitol | The serum concentration of Magnesium aspartate can be increased when it is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The serum concentration of Magnesium aspartate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The serum concentration of Magnesium aspartate can be increased when it is combined with Elocalcitol. |
| Maxacalcitol | The serum concentration of Magnesium aspartate can be increased when it is combined with Maxacalcitol. |
| Doxercalciferol | The serum concentration of Magnesium aspartate can be increased when it is combined with Doxercalciferol. |
| 1alpha-Hydroxyvitamin D5 | The serum concentration of Magnesium aspartate can be increased when it is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The serum concentration of Magnesium aspartate can be increased when it is combined with Previtamin D(3). |
| Deferiprone | Magnesium aspartate can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Magnesium aspartate can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Magnesium aspartate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferasirox | Magnesium aspartate can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Magnesium aspartate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Misoprostol | The risk or severity of adverse effects can be increased when Magnesium aspartate is combined with Misoprostol. |
| Moxifloxacin | Magnesium aspartate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Grepafloxacin | Magnesium aspartate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enoxacin | Magnesium aspartate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pefloxacin | Magnesium aspartate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofloxacin | Magnesium aspartate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Trovafloxacin | Magnesium aspartate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nalidixic acid | Magnesium aspartate can cause a decrease in the absorption of Nalidixic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosoxacin | Magnesium aspartate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cinoxacin | Magnesium aspartate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lomefloxacin | Magnesium aspartate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gatifloxacin | Magnesium aspartate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norfloxacin | Magnesium aspartate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levofloxacin | Magnesium aspartate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ofloxacin | Magnesium aspartate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sparfloxacin | Magnesium aspartate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Temafloxacin | Magnesium aspartate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fleroxacin | Magnesium aspartate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Technetium Tc-99m ciprofloxacin | Magnesium aspartate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Garenoxacin | Magnesium aspartate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nemonoxacin | Magnesium aspartate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Flumequine | Magnesium aspartate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Enrofloxacin | Magnesium aspartate can cause a decrease in the absorption of Enrofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Orbifloxacin | Magnesium aspartate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarafloxacin | Magnesium aspartate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Difloxacin | Magnesium aspartate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pazufloxacin | Magnesium aspartate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prulifloxacin | Magnesium aspartate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delafloxacin | Magnesium aspartate can cause a decrease in the absorption of Delafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sitafloxacin | Magnesium aspartate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxolinic acid | Magnesium aspartate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rufloxacin | Magnesium aspartate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pipemidic acid | Magnesium aspartate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lymecycline | Magnesium aspartate can cause a decrease in the absorption of Lymecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clomocycline | Magnesium aspartate can cause a decrease in the absorption of Clomocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oxytetracycline | Magnesium aspartate can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demeclocycline | Magnesium aspartate can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetracycline | Magnesium aspartate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metacycline | Magnesium aspartate can cause a decrease in the absorption of Metacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Minocycline | Magnesium aspartate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sarecycline | Magnesium aspartate can cause a decrease in the absorption of Sarecycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omadacycline | Magnesium aspartate can cause a decrease in the absorption of Omadacycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Penimepicycline | Magnesium aspartate can cause a decrease in the absorption of Penimepicycline resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Isradipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Isradipine. |
| Diltiazem | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Diltiazem. |
| Trimethadione | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Trimethadione. |
| Amlodipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Amlodipine. |
| Nimodipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Nimodipine. |
| Nisoldipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Nisoldipine. |
| Lercanidipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Lercanidipine. |
| Cinnarizine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Cinnarizine. |
| Ethosuximide | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Ethosuximide. |
| Nicardipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Nicardipine. |
| Magnesium sulfate | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Magnesium sulfate. |
| Verapamil | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Verapamil. |
| Zonisamide | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Zonisamide. |
| Felodipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Felodipine. |
| Nitrendipine | The risk or severity of hypotension can be increased when Magnesium aspartate is combined with Nitrendipine. |